Enanta Pharmaceuticals (ENTA)
NASDAQ:ENTA
ENTA Stock Chart & Stats
$12.17
-$0.16(-2.97%)
At close: 4:00 PM EST
$12.17
-$0.16(-2.97%)
Day’s Range― - ―
52-Week Range$4.09 - $17.15
Previous CloseN/A
Volume330.58K
Average Volume (3M)176.31K
Market Cap
$353.17M
Enterprise Value$438.29M
Total Cash (Recent Filing)$185.85M
Total Debt (Recent Filing)$193.18M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
May 11, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding29,019,344
10 Day Avg. Volume167,853
30 Day Avg. Volume176,309
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.95
Price to Sales (P/S)3.91
P/FCF Ratio-7.94
Enterprise Value/Market Cap1.24
Enterprise Value/Revenue6.54
Enterprise Value/Gross Profit6.54
Enterprise Value/Ebitda-7.43
Forecast
1Y Price Target
$19.67Price Target Upside61.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.76
Revenue Forecast (FY)$65.78M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsAnalyst notes that positive Phase 2b results for zelicapavir showed meaningful clinical benefit with consistent virologic and safety findings, supporting the case the drug could be approvable if replicated in a pivotal trial.
Pipeline DiversificationExpansion of the immunology pipeline, including a KIT inhibitor approaching phase 1 and a new MRGPRX2 program, increases the chance of early clinical milestones and broadens therapeutic opportunities beyond the lead antiviral.
Regulatory PathwayAlignment with the FDA on a single pivotal-trial design would provide regulatory clarity and materially strengthen the late-stage development strategy for zelicapavir.
Bears Say
Approval UncertaintyRegulatory approval depends on replication of Phase 2b findings in a pivotal trial, creating substantial development and execution risk if efficacy or safety are not confirmed.
Partnering And Funding RiskUncertainty about whether a development partner is required to initiate a pivotal trial could delay progress or force reliance on external funding, limiting independent control over late-stage development.
Regulatory HeadlinesHeadlines from a senior regulatory official about RSV vaccines for infants caused share volatility and heightened negative sentiment toward RSV-related programs.
Enanta Pharmaceuticals News
ENTA FAQ
What was Enanta Pharmaceuticals’s price range in the past 12 months?
Enanta Pharmaceuticals lowest stock price was $4.09 and its highest was $17.15 in the past 12 months.
What is Enanta Pharmaceuticals’s market cap?
Enanta Pharmaceuticals’s market cap is $353.17M.
When is Enanta Pharmaceuticals’s upcoming earnings report date?
Enanta Pharmaceuticals’s upcoming earnings report date is May 11, 2026 which is in 46 days.
How were Enanta Pharmaceuticals’s earnings last quarter?
Enanta Pharmaceuticals released its earnings results on Feb 09, 2026. The company reported -$0.42 earnings per share for the quarter, beating the consensus estimate of -$0.768 by $0.348.
Is Enanta Pharmaceuticals overvalued?
According to Wall Street analysts Enanta Pharmaceuticals’s price is currently Undervalued.
Does Enanta Pharmaceuticals pay dividends?
Enanta Pharmaceuticals does not currently pay dividends.
What is Enanta Pharmaceuticals’s EPS estimate?
Enanta Pharmaceuticals’s EPS estimate is -0.51.
How many shares outstanding does Enanta Pharmaceuticals have?
Enanta Pharmaceuticals has 29,019,344 shares outstanding.
What happened to Enanta Pharmaceuticals’s price movement after its last earnings report?
Enanta Pharmaceuticals reported an EPS of -$0.42 in its last earnings report, beating expectations of -$0.768. Following the earnings report the stock price went up 2.169%.
Which hedge fund is a major shareholder of Enanta Pharmaceuticals?
Currently, no hedge funds are holding shares in ENTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enanta Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.67 (61.63% Upside)
$19.67 (61.63% Upside)
Blogger Sentiment
Bullish
ENTA Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 612.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
106.97%
12-Months-Change
Fundamentals
Return on Equity
-78.59%
Trailing 12-Months
Asset Growth
-5.49%
Trailing 12-Months
Company Description
Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
ENTA Stock 12 Month Forecast
Average Price Target
$19.67
▲(61.63% Upside)
Technical Analysis
Abeona Therapeutics
―
Tectonic Therapeutic
―
Allogene Therapeutics
―
Jade Biosciences
―
Neumora Therapeutics, Inc.
―
Ownership Overview
4.76% Insiders
11.99% Mutual Funds
31.57% Other Institutional Investors
41.03% Public Companies and
Individual Investors